Jinfang Hongrui Capital

  • Immunophage closes near-RMB100m Pre A

    Immunophage has recently completed a Pre-A round of financing of nearly 100 million yuan, led by Jinfang Hongrui Capital, with participation from five institutions including Ennovation Venture Capital and Yang Zi Investment Group. The proceeds will be mainly used to promote the company’s two core product lines for IND clinical declaration and early development of more than two new drug projects.